Profile data is unavailable for this security.
About the company
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
- Revenue in NOK (TTM)500.66m
- Net income in NOK267.00k
- Incorporated1995
- Employees106.00
- LocationPhotocure ASAHoffsveien 4OSLO 0275NorwayNOR
- Phone+47 22062210
- Fax+47 22062218
- Websitehttps://photocure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alligator Bioscience AB | 58.65m | -250.89m | 801.52m | 58.00 | -- | 55.25 | -- | 13.67 | -0.5613 | -0.5613 | 0.1205 | 0.018 | 0.4035 | -- | 8.34 | 1,001,845.00 | -172.61 | -73.26 | -399.57 | -91.33 | -- | -- | -427.81 | -811.68 | -- | -- | 0.5759 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Moberg Pharma AB (publ) | 0.00 | -21.29m | 857.84m | -- | -- | 1.37 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| Diamyd Medical AB | 284.62k | -121.30m | 949.98m | 26.00 | -- | 4.86 | -- | 3,337.74 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -181.34m | 1.02bn | 26.00 | -- | 1.83 | -- | -- | -7.02 | -7.02 | 0.00 | 22.19 | 0.00 | -- | -- | 0.00 | -26.60 | -18.38 | -28.03 | -19.26 | -- | -- | -- | -- | 4.36 | -- | 0.0504 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Vistin Pharma ASA | 438.33m | 45.64m | 1.07bn | 79.00 | 23.51 | 3.32 | 17.04 | 2.45 | 1.03 | 1.03 | 9.88 | 7.28 | 1.09 | 2.16 | 7.75 | -- | 11.33 | 1.73 | 14.64 | 2.11 | 59.70 | 59.01 | 10.41 | 2.36 | 1.30 | 6.81 | -- | -- | 52.37 | 17.11 | 1,067.85 | -- | -0.2357 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -124.21m | 1.15bn | 8.00 | -- | 3.85 | -- | -- | -9.90 | -9.90 | 0.00 | 22.65 | 0.00 | -- | -- | 0.00 | -35.11 | -16.11 | -38.65 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -48.55m | 1.22bn | 5.00 | -- | 4.65 | -- | -- | -0.241 | -0.241 | 0.00 | 0.9258 | 0.00 | -- | -- | 0.00 | -19.22 | -16.81 | -20.75 | -18.26 | -- | -- | -- | -- | -- | -12.92 | 0.1734 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| SyntheticMR AB (publ) | 90.04m | 10.10m | 1.22bn | 37.00 | 119.02 | 10.40 | 74.63 | 13.60 | 0.2445 | 0.2445 | 2.17 | 2.80 | 0.6599 | -- | 1.61 | 2,411,162.00 | 7.41 | 7.19 | 8.89 | 8.85 | 105.78 | 106.74 | 11.22 | 9.08 | -- | 14.13 | 0.0107 | 21.50 | 30.67 | 13.05 | 70.34 | -7.33 | 26.79 | -- |
| Arcticzymes Technologies ASA | 118.94m | 18.72m | 1.33bn | 61.00 | 70.65 | 4.31 | 52.98 | 11.18 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
| Photocure ASA | 500.66m | 267.00k | 1.48bn | 106.00 | 7,576.60 | 3.06 | 52.77 | 2.95 | 0.0072 | 0.0072 | 18.58 | 17.79 | 0.7001 | 0.8203 | 9.37 | -- | 0.0375 | -3.09 | 0.0429 | -3.56 | 94.78 | 93.64 | 0.0535 | -5.19 | 4.32 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
| Hansa Biopharma AB | 167.42m | -852.72m | 1.50bn | 166.00 | -- | -- | -- | 8.94 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| BioInvent International AB | 72.12m | -333.37m | 1.55bn | 111.00 | -- | 1.17 | -- | 21.46 | -5.02 | -5.02 | 1.09 | 19.90 | 0.0459 | -- | 5.16 | 643,792.80 | -21.23 | -17.50 | -22.40 | -18.64 | -- | -- | -462.22 | -131.63 | 14.77 | -- | 0.0174 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Devyser Diagnostics AB | 170.87m | -54.10m | 1.68bn | 118.00 | -- | 4.33 | -- | 9.86 | -3.31 | -3.31 | 10.46 | 23.65 | 0.335 | 1.59 | 5.53 | 1,434,746.00 | -10.65 | -8.97 | -12.00 | -10.15 | 85.53 | 80.14 | -31.78 | -23.91 | 5.11 | -- | 0.1626 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Genovis AB | 159.70m | 62.07m | 1.78bn | 37.00 | 28.64 | 9.23 | 24.73 | 11.13 | 0.9394 | 0.9394 | 2.42 | 2.91 | 0.7203 | -- | -- | 4,276,514.00 | 27.99 | 18.56 | 30.74 | 21.45 | 72.20 | 65.51 | 38.87 | 23.88 | -- | -- | -- | -- | 54.54 | 35.56 | 449.56 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 58.03m | -329.83m | 1.85bn | 27.00 | -- | 3.36 | -- | 31.85 | -1.28 | -1.28 | 0.224 | 1.86 | 0.087 | 16.92 | 3.59 | 2,129,630.00 | -49.44 | -33.02 | -55.92 | -36.46 | 80.87 | -- | -568.00 | -357.72 | 3.32 | -- | 0.1688 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Vicore Pharma Holding AB | 0.00 | -313.83m | 1.91bn | 24.00 | -- | 4.16 | -- | -- | -3.24 | -3.24 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -74.40 | -58.65 | -83.09 | -65.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Data as of Apr 22 2024. Currency figures normalised to Photocure ASA's reporting currency: Norwegian Krone NOK
35.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Briarwood Chase Management LLCas of 04 May 2023 | 3.86m | 14.23% |
| Lannebo Fonder ABas of 04 May 2023 | 1.79m | 6.62% |
| SEB Investment Management ABas of 29 Sep 2023 | 1.34m | 4.93% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 804.81k | 2.97% |
| MP Pensjon PKas of 04 May 2023 | 478.03k | 1.76% |
| KLP Kapitalforvaltning ASas of 31 Mar 2023 | 375.63k | 1.39% |
| Equinor Asset Management ASAas of 30 Jun 2023 | 258.57k | 0.95% |
| DNB Asset Management ASas of 29 Feb 2024 | 257.11k | 0.95% |
| Pareto Asset Management ASas of 30 Nov 2023 | 206.00k | 0.76% |
| Coeli Asset Management ABas of 30 Jun 2021 | 185.21k | 0.68% |
More ▼
Data from 30 Jun 2023 - 19 Apr 2024Source: FactSet Research Systems Inc.
